AbobotulinumtoxinA Treatment of Glabellar Lines Using a New Reconstitution and Injection Volume: Randomized, Placebo-Controlled Data

September 2021 | Volume 20 | Issue 9 | Original Article | 988 | Copyright © September 2021


Published online August 27, 2021

Joel Schlessinger MDa, Daniel P. Friedmann MDb, Flor Mayoral MDc, Deanne Mraz Robinson MDd, DeeAnna Glaser MDe, Douglas Wu MDf, Keith Marcus MDg, Michael Somenek MDh, Xiaoming Lin RN MSi

aSkin Specialists, Omaha, NE
bWestlake Dermatology Clinical Research Center, Austin, TX
cFlor Mayoral, MD, Coral Gables, FL
dModern Dermatology, Westport, CT
eSaint Louis University, St. Louis, MO
fDermatology Cosmetic Laser Medical Associates of La Jolla, San Diego, CA
gMarcus Facial Plastic Surgery, Redondo Beach, CA
hAdvanced Plastic Surgery, Washington, D.C.
iGalderma Laboratories, Fort Worth, TX

The study population consisted of 88% women and 92% White subjects. Randomized subjects were aged between 21 and 66 years, mean, 44.1 years, and 52% were toxin naive. More details are provided in Table 1.

Efficacy
Time to Onset of Response
The median subject-reported time to onset of effect was 2.0 days after aboBoNT-A treatment based on the subject diary, with 34% reporting onset on day 1 and 60% by day 2 (Figure 1). For placebo, no median time to onset could be calculated due to few subjects reporting an effect (11 of 77).

The investigator assessments of GL severity (ILA) at day 2 showed 47% of subjects with none or mild GL severity and